MAPT and tauopathy: Inhibition of Hsp90 in both cellular and mouse models of tauopathies by Hsp90 inhibitors of the purine-scaffold class [35] led to the reduction of the aberrant activity of these proteins and resulted in a decrease of aggregated tau.